Alper Onder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alper Onder has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ferah Comert Onder
Çanakkale Onsekiz Mart University
10 shared publications Hava Ozay
5 shared publications- Mehmet Ay
Çanakkale Onsekiz Mart University
5 shared publications - Ozgur Ozay
Laboratory of Biomaterials Research, Department of Bioengineering, Faculty of Engineering, Çanakkale Onsekiz Mart University
4 shared publications Pinar Ilgin
3 shared publications- Bulent Ozpolat
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (35) , 52714-52730
Design, Synthesis, In Vitro Biological Evaluation, and In Silico Analyses of Novel Pyrano[3,4- b ]indole-Containing Compounds as Promising Multitarget Candidates for Alzheimer’s Disease and Cancer Therapy
Alzheimer’s disease (AD) is a neurodegenerative disease associated with decreased activity of the cholinergic system in the brain. Identifying a drug that has no side effects and can prevent or delay the progression of this neurodegenerative disease is crucial. In this study, 11 novel pyrano[3,4-b]indole derivatives (ECA-ECM) were designed and synthesized as AChE and BChE inhibitors, and their structures were elucidated by spectroscopic analyses. Enzyme activity studies were conducted in vitro. Inhibitory potentials for both cholinesterase enzymes were determined by in silico analyses, and protein–ligand interactions were elucidated. The ECB compound (AChE IC50 = 35.31 ± 0.81 nM and BChE IC50 = 28.91 ± 0.19 nM) is a potential candidate as a dual AChE/BChE inhibitor. These findings indicate that the synthesized pyrano[3,4-b]indole derivatives have inhibitory potential for AD. The cytotoxic activities of the synthesized compounds were evaluated in vitro. The ECK compound showed a strong cytotoxic effect in five different human cancer cell lines in the ranging concentrations from 10.37 ± 1.43 to 29.34 ± 1.71 μM. The ECD compound exhibited strong cytotoxic activity at a concentration of 9.27 ± 0.97 μM in the colon cancer cell line. The cytotoxic activities of ECK and ECM were found to be below 25 μM in four human cancer cell lines. In silico analyses, including molecular docking, molecular dynamics simulations, and binding free energy calculations, confirmed that the synthesized compounds are potential candidates targeting AChE and BChE. Consequently, the synthesized compounds showed promising results for the treatment of AD and cancer.
- 26 August 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (35) , 52714-52730
Open AccessDesign, Synthesis, In Vitro Biological Evaluation, and In Silico Analyses of Novel Pyrano[3,4- b ]indole-Containing Compounds as Promising Multitarget Candidates for Alzheimer’s Disease and Cancer Therapy
Alzheimer’s disease (AD) is a neurodegenerative disease associated with decreased activity of the cholinergic system in the brain. Identifying a drug that has no side effects and can prevent or delay the progression of this neurodegenerative disease is crucial. In this study, 11 novel pyrano[3,4-b]indole derivatives (ECA-ECM) were designed and synthesized as AChE and BChE inhibitors, and their structures were elucidated by spectroscopic analyses. Enzyme activity studies were conducted in vitro. Inhibitory potentials for both cholinesterase enzymes were determined by in silico analyses, and protein–ligand interactions were elucidated. The ECB compound (AChE IC50 = 35.31 ± 0.81 nM and BChE IC50 = 28.91 ± 0.19 nM) is a potential candidate as a dual AChE/BChE inhibitor. These findings indicate that the synthesized pyrano[3,4-b]indole derivatives have inhibitory potential for AD. The cytotoxic activities of the synthesized compounds were evaluated in vitro. The ECK compound showed a strong cytotoxic effect in five different human cancer cell lines in the ranging concentrations from 10.37 ± 1.43 to 29.34 ± 1.71 μM. The ECD compound exhibited strong cytotoxic activity at a concentration of 9.27 ± 0.97 μM in the colon cancer cell line. The cytotoxic activities of ECK and ECM were found to be below 25 μM in four human cancer cell lines. In silico analyses, including molecular docking, molecular dynamics simulations, and binding free energy calculations, confirmed that the synthesized compounds are potential candidates targeting AChE and BChE. Consequently, the synthesized compounds showed promising results for the treatment of AD and cancer.
- Open Access
- 3 May 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (3) , e70296
Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship
Triple Negative Breast Cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC), which is associated with a very poor prognosis. It is a broad category of tumors with a variety of biological, clinical, and morphological characteristics. FOXM1 is a pivotal transcription factor that modulates proliferation‐associated genes through complex protein‐DNA and protein‐protein interactions, making it a highly attractive target in cancer therapy. However, existing small‐molecule inhibitors often suffer from limited specificity and efficacy. In this study, we designed, synthesized, and evaluated novel series of 2‐aminothiazole derivatives ( C1‐C15) as potential FOXM1 inhibitors. Molecular docking and molecular dynamics (MD) simulations were employed to investigate the binding interactions of these compounds with the FOXM1 DNA‐binding domain (FOXM1‐DBD). Structural analysis highlighted the importance of crucial residues, including Asn283, His287, and Arg286, in mediating inhibitory activity. Among the synthesized compounds, C11 exhibited remarkable structural alignment and interaction patterns with FOXM1‐DBD, comparable to the reference inhibitor FDI‐6. In vitro studies using TNBC cell lines (MDA‐MB‐231, BT‐549, and BT‐20) demonstrated that compound C11 significantly outperformed FDI‐6 in potency. Western blot analysis revealed that C11 effectively suppressed FOXM1 transcriptional activity at concentrations of 10 µM in BT‐549 cells and 20 µM in MDA‐MB‐231 cells. These findings underscore the potential of C11 as a potent FOXM1 inhibitor and highlight its promise for further development in TNBC therapy.
- 3 May 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (3) , e70296
Open AccessDesign, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship
Triple Negative Breast Cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC), which is associated with a very poor prognosis. It is a broad category of tumors with a variety of biological, clinical, and morphological characteristics. FOXM1 is a pivotal transcription factor that modulates proliferation‐associated genes through complex protein‐DNA and protein‐protein interactions, making it a highly attractive target in cancer therapy. However, existing small‐molecule inhibitors often suffer from limited specificity and efficacy. In this study, we designed, synthesized, and evaluated novel series of 2‐aminothiazole derivatives ( C1‐C15) as potential FOXM1 inhibitors. Molecular docking and molecular dynamics (MD) simulations were employed to investigate the binding interactions of these compounds with the FOXM1 DNA‐binding domain (FOXM1‐DBD). Structural analysis highlighted the importance of crucial residues, including Asn283, His287, and Arg286, in mediating inhibitory activity. Among the synthesized compounds, C11 exhibited remarkable structural alignment and interaction patterns with FOXM1‐DBD, comparable to the reference inhibitor FDI‐6. In vitro studies using TNBC cell lines (MDA‐MB‐231, BT‐549, and BT‐20) demonstrated that compound C11 significantly outperformed FDI‐6 in potency. Western blot analysis revealed that C11 effectively suppressed FOXM1 transcriptional activity at concentrations of 10 µM in BT‐549 cells and 20 µM in MDA‐MB‐231 cells. These findings underscore the potential of C11 as a potent FOXM1 inhibitor and highlight its promise for further development in TNBC therapy.
- 3 July 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (13) , 1559-1573
Design, synthesis, characterization, in silico studies, and in vitro anticancer evaluation of novel 7-methoxyquinolone-substituted triazole hybrids
The quinolone scaffold is a crucial member of the heterocyclic compound family in modern medicinal chemistry, exhibiting a broad range of biological activities. Since 4-quinolones are known to interact with significant drug targets, and due to the remarkable pharmacological properties of 1,2,3-triazole compounds, a molecular hybridization approach was used to design novel 7-methoxyquinolone-substituted triazole hybrid conjugates (QN1-QN11). These hybrid compounds were evaluated to determine their anticancer activities in various breast and colon cancer cell lines, including BT20, MDA-MB-231, MCF7, and HT29. In addition, the apoptotic-like morphological changes in aggressive MDA-MB-231 cells were observed following treatment with the compounds for 48 hours. In silico studies, including molecular docking, molecular dynamics (MD) simulation, and MM/GBSA calculations, were carried out for the synthesized compounds against important cancer drug targets. The highly cytotoxic agents QN10 and QN7 were identified with IC50 values of 4.49 ± 0.68 µM and 19.05 ± 1.58 µM in BT20 and HT29 cell lines, respectively. In addition, the morphologically changes were observed on MDA-MB-231 cells. These findings show that the synthesized click products are highly cytotoxic agents in cancer cell lines and may be considered as potential candidates for enzyme inhibition.
- 3 July 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (13) , 1559-1573
Design, synthesis, characterization, in silico studies, and in vitro anticancer evaluation of novel 7-methoxyquinolone-substituted triazole hybrids
The quinolone scaffold is a crucial member of the heterocyclic compound family in modern medicinal chemistry, exhibiting a broad range of biological activities. Since 4-quinolones are known to interact with significant drug targets, and due to the remarkable pharmacological properties of 1,2,3-triazole compounds, a molecular hybridization approach was used to design novel 7-methoxyquinolone-substituted triazole hybrid conjugates (QN1-QN11). These hybrid compounds were evaluated to determine their anticancer activities in various breast and colon cancer cell lines, including BT20, MDA-MB-231, MCF7, and HT29. In addition, the apoptotic-like morphological changes in aggressive MDA-MB-231 cells were observed following treatment with the compounds for 48 hours. In silico studies, including molecular docking, molecular dynamics (MD) simulation, and MM/GBSA calculations, were carried out for the synthesized compounds against important cancer drug targets. The highly cytotoxic agents QN10 and QN7 were identified with IC50 values of 4.49 ± 0.68 µM and 19.05 ± 1.58 µM in BT20 and HT29 cell lines, respectively. In addition, the morphologically changes were observed on MDA-MB-231 cells. These findings show that the synthesized click products are highly cytotoxic agents in cancer cell lines and may be considered as potential candidates for enzyme inhibition.
- 18 June 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (12) , 1377-1389
New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers
In this study, new boron-containing carbamate compounds were synthesized and evaluated as potential acetylcholinesterase (AChE) inhibitors by in vitro and in silico analyses. The structures were characterized by spectroscopic analysis including 1H NMR, 13C NMR, 11B NMR, and MS. The purities of the compounds were determined by HPLC analysis. In vitro and in silico analyses were performed. Based on our findings, compounds (1-4) demonstrated more potent AChE inhibitory activity compared to tacrine, which is an FDA-approved AChE inhibitor. Compound 4 had the highest inhibitory activity with an IC50 of 37.87 ± 0.96 nM and was more effective than tacrine (74.23 ± 0.83 nM). Compounds 1, 2, and 3, respectively, showed 1.78-, 1.73-, and 1.58-fold more potent enzyme inhibition activity compared to tacrine. The strong interactions with critical residues in the binding pocket of AChE were identified between protein and the compounds. Furthermore, compound 4 exerted an antiproliferative activity against various human cancer cell lines (32.91 ± 4.92 µM in HT29 and 42.38 ± 2.73 µM in MCF-7). Our study indicates the discovery of new boron-containing AChE inhibitors as potential candidates for the treatment of Alzheimer's disease and cancer.
- 18 June 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (12) , 1377-1389
New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers
In this study, new boron-containing carbamate compounds were synthesized and evaluated as potential acetylcholinesterase (AChE) inhibitors by in vitro and in silico analyses. The structures were characterized by spectroscopic analysis including 1H NMR, 13C NMR, 11B NMR, and MS. The purities of the compounds were determined by HPLC analysis. In vitro and in silico analyses were performed. Based on our findings, compounds (1-4) demonstrated more potent AChE inhibitory activity compared to tacrine, which is an FDA-approved AChE inhibitor. Compound 4 had the highest inhibitory activity with an IC50 of 37.87 ± 0.96 nM and was more effective than tacrine (74.23 ± 0.83 nM). Compounds 1, 2, and 3, respectively, showed 1.78-, 1.73-, and 1.58-fold more potent enzyme inhibition activity compared to tacrine. The strong interactions with critical residues in the binding pocket of AChE were identified between protein and the compounds. Furthermore, compound 4 exerted an antiproliferative activity against various human cancer cell lines (32.91 ± 4.92 µM in HT29 and 42.38 ± 2.73 µM in MCF-7). Our study indicates the discovery of new boron-containing AChE inhibitors as potential candidates for the treatment of Alzheimer's disease and cancer.
- Open Access
- 16 November 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (47) , 46860-46878
Novel Dibenzoazepine-Substituted Triazole Hybrids as Cholinesterase and Carbonic Anhydrase Inhibitors and Anticancer Agents: Synthesis, Characterization, Biological Evaluation, and In Silico Studies
The new dibenzoazepine-substituted triazole hybrids (12–20) were designed by molecular hybridization approach and synthesized utilizing the Cu(I)-catalyzed click reaction. The hybrid structures (12–20) were obtained in high yields (74–98%) with a simple two-step synthesis strategy and fully characterized. These compounds were assessed for their influence on various metabolic enzymes including human carbonic anhydrase isoenzymes (hCA I and hCA II), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). The Ki values for the compounds concerning hCA I, hCA II, AChE, and BChE enzymes were in the ranges 29.94–121.69, 17.72–89.42, 14.09–44.68, and 1.15–48.82 nM, respectively. Compound 13 was 49.70-fold more active than tacrine (standard drug) for BChE and 5.49-fold for AChE. Compound 14 was 4.16-fold more active than acetazolamide (standard drug) for hCA I and 5.79-fold for hCA II. The cytotoxic effects of the synthesized click products were investigated on human triple-negative breast cancer cell lines. The IC50 values of the most effective compounds were calculated between 12.51 ± 1.92 and 18.07 ± 2.14 μM in MDA-MB-231 and BT-549 cells. Molecular docking and ADME predictions were performed. Then, in vitro effective compounds were analyzed by molecular dynamics (MD) simulation and MM/GBSA calculation. Consequently, click products showed good cytotoxicity and inhibition potential on colony formation in cancer cells.
- 16 November 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (47) , 46860-46878
Open AccessNovel Dibenzoazepine-Substituted Triazole Hybrids as Cholinesterase and Carbonic Anhydrase Inhibitors and Anticancer Agents: Synthesis, Characterization, Biological Evaluation, and In Silico Studies
The new dibenzoazepine-substituted triazole hybrids (12–20) were designed by molecular hybridization approach and synthesized utilizing the Cu(I)-catalyzed click reaction. The hybrid structures (12–20) were obtained in high yields (74–98%) with a simple two-step synthesis strategy and fully characterized. These compounds were assessed for their influence on various metabolic enzymes including human carbonic anhydrase isoenzymes (hCA I and hCA II), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). The Ki values for the compounds concerning hCA I, hCA II, AChE, and BChE enzymes were in the ranges 29.94–121.69, 17.72–89.42, 14.09–44.68, and 1.15–48.82 nM, respectively. Compound 13 was 49.70-fold more active than tacrine (standard drug) for BChE and 5.49-fold for AChE. Compound 14 was 4.16-fold more active than acetazolamide (standard drug) for hCA I and 5.79-fold for hCA II. The cytotoxic effects of the synthesized click products were investigated on human triple-negative breast cancer cell lines. The IC50 values of the most effective compounds were calculated between 12.51 ± 1.92 and 18.07 ± 2.14 μM in MDA-MB-231 and BT-549 cells. Molecular docking and ADME predictions were performed. Then, in vitro effective compounds were analyzed by molecular dynamics (MD) simulation and MM/GBSA calculation. Consequently, click products showed good cytotoxicity and inhibition potential on colony formation in cancer cells.
- Open Access
- 30 September 2024
- Published by Canakkale Onsekiz Mart University in Journal of Advanced Research in Natural and Applied Sciences
- Vol. 10 (3) , 659-668
Effects of Pleurotus Eryngii (DC.) Quél. Mushroom Extracts on Cell Proliferation in Breast and Colon Cancer Cell Lines
This study was aimed to collect Pleurotus eryngii (DC.) Quél. edible/medicinal mushroom from Çanakkale/Kumkale and to evaluate the antiproliferative effects of alcoholic extracts on breast and colon cancer cell lines. For this purpose, the Soxhlet method prepared methanol and ethanol:H2O (70:30) extracts by gradually increasing solvent polarities. Then, breast (MDA-MB-231, BT-549, BT-20, MCF-7) and colon (HT-29) cancer cell lines were treated with the extracts in increasing concentrations (0.05-0.5 mg/mL) for 48 h. In conclusion, methanol and aqueous ethanol extracts exhibited significant antiproliferative effects in cancer cell lines, according to the MTT assay. The cell viability in the triple-negative breast cancer (TNBC) MDA-MB-231 cell line was highly decreased by methanol extract at a very low concentration (0.1 mg/mL). Furthermore, methanol extract at 0.3 mg/mL reduced the percentage of cell viability in the HT-29 cell line. Aqueous ethanol extract showed antiproliferative activity in breast and colon cancer cell lines at 0.25 mg/mL concentration for 48 h applications. In addition, some bioactive components such as 4-hydroxy flavone, chrysin, and tannic acid of aqueous ethanol extract have been determined by High-Performance Liquid Chromatography (HPLC) analysis. As a result, this study may increase interest in the studies on the anti-cancer activities and the mechanisms of P. eryngii mushroom.
- 30 September 2024
- Published by Canakkale Onsekiz Mart University in Journal of Advanced Research in Natural and Applied Sciences
- Vol. 10 (3) , 659-668
Open AccessEffects of Pleurotus Eryngii (DC.) Quél. Mushroom Extracts on Cell Proliferation in Breast and Colon Cancer Cell Lines
This study was aimed to collect Pleurotus eryngii (DC.) Quél. edible/medicinal mushroom from Çanakkale/Kumkale and to evaluate the antiproliferative effects of alcoholic extracts on breast and colon cancer cell lines. For this purpose, the Soxhlet method prepared methanol and ethanol:H2O (70:30) extracts by gradually increasing solvent polarities. Then, breast (MDA-MB-231, BT-549, BT-20, MCF-7) and colon (HT-29) cancer cell lines were treated with the extracts in increasing concentrations (0.05-0.5 mg/mL) for 48 h. In conclusion, methanol and aqueous ethanol extracts exhibited significant antiproliferative effects in cancer cell lines, according to the MTT assay. The cell viability in the triple-negative breast cancer (TNBC) MDA-MB-231 cell line was highly decreased by methanol extract at a very low concentration (0.1 mg/mL). Furthermore, methanol extract at 0.3 mg/mL reduced the percentage of cell viability in the HT-29 cell line. Aqueous ethanol extract showed antiproliferative activity in breast and colon cancer cell lines at 0.25 mg/mL concentration for 48 h applications. In addition, some bioactive components such as 4-hydroxy flavone, chrysin, and tannic acid of aqueous ethanol extract have been determined by High-Performance Liquid Chromatography (HPLC) analysis. As a result, this study may increase interest in the studies on the anti-cancer activities and the mechanisms of P. eryngii mushroom.
- Open Access
- 31 May 2024
- Published by International Society of Academicians in International Journal of Life Sciences and Biotechnology
- Vol. 7 (2) , 88-101
Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Studies on Potential Phytochemicals as Sphingosine Kinase 1 Inhibitors for Cancer Therapy
Sphingosine kinases (SphKs) as lipid kinases catalyze the phosphorylation of sphingosine (Sph) to sphingosine-1-phosphate (S1P). Targeting the S1P signaling pathway is a significant strategy for many human diseases. Herein, we evaluated main prenylated bioactive components of a medicinal plant and performed a virtual screening study with flavonoid compounds and then, molecular docking and molecular dynamics (MD) simulation for the targeted cancer therapy. In silico ADMET and drug-likeness results were determined by BIOVIA Discovery Studio (DS). Molecular docking and molecular dynamics (MD) simulations were carried out by using Glide/SP and Desmond of Maestro with the filtered ligands. Glide/SP docking results showed higher binding affinity with xanthohumol (XN), 8-prenylnaringenin (8-PN), and neobavaisoflavone against SphK1. Three hits displayed strong hydrogen binding between the specific amino acid residues of targeting SphK1. There were no significant structural changes between SphK1-XN and SphK1-neobavaisoflavone complexes during 200 ns MD simulation analysis performed by GROMACS. Root-mean square deviation (RMSD) average values of XN- and neobavaisoflavone-protein complexes were compared to free SphK1 and were found as 0.2626 nm, 0.2589 nm, and 0.2508 nm, respectively. As a result, XN and 8-PN, and neobavaisoflavone have been determined as potential inhibitor candidates of SphK1 to examine for further in vitro and in vivo studies.
- 31 May 2024
- Published by International Society of Academicians in International Journal of Life Sciences and Biotechnology
- Vol. 7 (2) , 88-101
Open AccessVirtual Screening, Molecular Docking, and Molecular Dynamics Simulation Studies on Potential Phytochemicals as Sphingosine Kinase 1 Inhibitors for Cancer Therapy
Sphingosine kinases (SphKs) as lipid kinases catalyze the phosphorylation of sphingosine (Sph) to sphingosine-1-phosphate (S1P). Targeting the S1P signaling pathway is a significant strategy for many human diseases. Herein, we evaluated main prenylated bioactive components of a medicinal plant and performed a virtual screening study with flavonoid compounds and then, molecular docking and molecular dynamics (MD) simulation for the targeted cancer therapy. In silico ADMET and drug-likeness results were determined by BIOVIA Discovery Studio (DS). Molecular docking and molecular dynamics (MD) simulations were carried out by using Glide/SP and Desmond of Maestro with the filtered ligands. Glide/SP docking results showed higher binding affinity with xanthohumol (XN), 8-prenylnaringenin (8-PN), and neobavaisoflavone against SphK1. Three hits displayed strong hydrogen binding between the specific amino acid residues of targeting SphK1. There were no significant structural changes between SphK1-XN and SphK1-neobavaisoflavone complexes during 200 ns MD simulation analysis performed by GROMACS. Root-mean square deviation (RMSD) average values of XN- and neobavaisoflavone-protein complexes were compared to free SphK1 and were found as 0.2626 nm, 0.2589 nm, and 0.2508 nm, respectively. As a result, XN and 8-PN, and neobavaisoflavone have been determined as potential inhibitor candidates of SphK1 to examine for further in vitro and in vivo studies.
- Open Access
- 15 March 2024
- Published by Canakkale Onsekiz Mart University in Journal of Advanced Research in Natural and Applied Sciences
- Vol. 10 (1) , 116-133
Anticancer, Antioxidant, Antimicrobial Activities, and HPLC Analysis of Alcoholic Extracts of Parthenocissus quinquefolia L. Plant Collected from Çanakkale
This study aimed to contribute to revealing the health effects of the Parthenocissus quinquefolia L. (PQ) plant by examining the biological activities of various extracts of the plant. An ethnobotanical important medicinal plant, PQ belongs to the Vine family (Vitaceae) and is known for its medicinal uses. Herein, fruit and leaf alcoholic extracts of the plant exhibited anticancer activity on triple negative breast cancer (TNBC) cell lines, estrogen receptor positive (ER+) (MCF-7), and human colon adenocarcinoma (HT-29) cancer cell lines. Furthermore, fruit methanol extracts displayed strong radical scavenging activity with low IC50 values such as 0.51 mg/mL, 0.80 mg/mL, 0.84 mg/mL, and 1.45 mg/mL. The highest TEAC values (18.72 mM Trolox/mg, 9.90 mM Trolox/mg, and 8.41 mM Trolox/mg) were calculated for the extracts of red leaves. The antifungal activity was determined against Candida albicans as fungal pathogen. The cell apoptosis with methanol extract was obtained between 20 µg/mL and 70 µg/mL for 48 h and 72 h treatments by Hoechst 33258 staining of nuclei under a fluorescence microscopy. HPLC analysis was performed for methanol extracts to determine major bioactive components. Consequently, this plant extracts may guide to new strategies and may be uses in medicinal applications for further investigations.
- 15 March 2024
- Published by Canakkale Onsekiz Mart University in Journal of Advanced Research in Natural and Applied Sciences
- Vol. 10 (1) , 116-133
Open AccessAnticancer, Antioxidant, Antimicrobial Activities, and HPLC Analysis of Alcoholic Extracts of Parthenocissus quinquefolia L. Plant Collected from Çanakkale
This study aimed to contribute to revealing the health effects of the Parthenocissus quinquefolia L. (PQ) plant by examining the biological activities of various extracts of the plant. An ethnobotanical important medicinal plant, PQ belongs to the Vine family (Vitaceae) and is known for its medicinal uses. Herein, fruit and leaf alcoholic extracts of the plant exhibited anticancer activity on triple negative breast cancer (TNBC) cell lines, estrogen receptor positive (ER+) (MCF-7), and human colon adenocarcinoma (HT-29) cancer cell lines. Furthermore, fruit methanol extracts displayed strong radical scavenging activity with low IC50 values such as 0.51 mg/mL, 0.80 mg/mL, 0.84 mg/mL, and 1.45 mg/mL. The highest TEAC values (18.72 mM Trolox/mg, 9.90 mM Trolox/mg, and 8.41 mM Trolox/mg) were calculated for the extracts of red leaves. The antifungal activity was determined against Candida albicans as fungal pathogen. The cell apoptosis with methanol extract was obtained between 20 µg/mL and 70 µg/mL for 48 h and 72 h treatments by Hoechst 33258 staining of nuclei under a fluorescence microscopy. HPLC analysis was performed for methanol extracts to determine major bioactive components. Consequently, this plant extracts may guide to new strategies and may be uses in medicinal applications for further investigations.